Bottom line
LYFAX vs FTXH: the short answer
LYFAX (AlphaCentric Life Sciences and Healthcare Fund) and FTXH (First Trust Nasdaq Pharmaceuticals ETF) are both mutual funds.
FTXH is cheaper at 0.6% vs 1.66% — a difference of $106 a year per $10,000 invested.
Over five years, FTXH returned +6.5% a year vs +4.1% for LYFAX.
LYFAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
LYFAX vs FTXH side by side
| LYFAX | FTXH | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Mutual | First Trust |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.66% | 0.6% |
| Annual cost per $10k | $166 | $60 |
| 10-yr cost on $10k (prospectus) | $3,039 | — |
| Max front load | 5.75% | None |
| 12b-1 fee | 0.25% | 0% |
| 1-yr return | +20.6% | +24.0% |
| 5-yr return (annualized) | +4.1% | +6.5% |
| 10-yr return (annualized) | — | — |
| Best quarter | +27.5% | +18.3% |
| Worst quarter | −11.9% | −17.4% |
| Net assets (fund) | $46.6M | $36.2M |
| Number of holdings | 62 | 51 |
| Portfolio turnover | 107% | 35% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | LYFAX | FTXH | Difference |
|---|---|---|---|
| 2025 | +27.9% | +24.0% | +3.9% |
| 2024 | −0.4% | +3.0% | −3.4% |
| 2023 | +6.9% | −1.4% | +8.3% |
| 2022 | −1.1% | +2.5% | −3.6% |
| 2021 | −3.6% | +6.1% | −9.7% |
| 2020 | +54.4% | +10.9% | +43.6% |
Source: Fund prospectus bar charts
Holdings overlap
8 of LYFAX's top 25 holdings also appear in FTXH's top 25.
| Holding | LYFAX | FTXH |
|---|---|---|
| Gilead Sciences Inc | 5.53% | 2.89% |
| Vertex Pharmaceuticals Inc | 5.33% | 3.41% |
| Neurocrine Biosciences Inc | 3.51% | 1.37% |
| Incyte Corp | 3.51% | 2.39% |
| Abbvie Inc | 1.95% | 7.39% |
| Amgen Inc | 1.83% | 3.18% |
| Biogen Inc | 1.80% | 3.84% |
| Halozyme Therapeutics Inc | 1.58% | 1.21% |
Source: SEC Form N-PORT
LYFAX top 10
- Gilead Sciences Inc — 5.53%
- Vertex Pharmaceuticals Inc — 5.33%
- Astrazeneca Plc — 4.63%
- First American Funds Inc — 4.26%
- Roivant Sciences Ltd — 3.67%
- Argenx Se — 3.59%
- Neurocrine Biosciences Inc — 3.51%
- Incyte Corp — 3.51%
- Axsome Therapeutics Inc — 3.43%
- Apogee Therapeutics Inc — 3.28%
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
FAQ
What is the difference between LYFAX and FTXH?
Which is cheaper, LYFAX or FTXH?
Should I own both LYFAX and FTXH?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.